Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Biochemical evaluation of kidney disease.

Treacy O, Brown NN, Dimeski G.

Transl Androl Urol. 2019 May;8(Suppl 2):S214-S223. doi: 10.21037/tau.2018.10.02. Review.

2.

TNF-α/IL-1β-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung.

Murphy N, Treacy O, Lynch K, Morcos M, Lohan P, Howard L, Fahy G, Griffin MD, Ryan AE, Ritter T.

FASEB J. 2019 Aug;33(8):9404-9421. doi: 10.1096/fj.201900047R. Epub 2019 May 20.

PMID:
31108041
3.

Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation.

Lohan P, Murphy N, Treacy O, Lynch K, Morcos M, Chen B, Ryan AE, Griffin MD, Ritter T.

Front Immunol. 2018 Nov 20;9:2666. doi: 10.3389/fimmu.2018.02666. eCollection 2018.

4.

Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer.

O'Malley G, Treacy O, Lynch K, Naicker SD, Leonard NA, Lohan P, Dunne PD, Ritter T, Egan LJ, Ryan AE.

Cancer Immunol Res. 2018 Nov;6(11):1426-1441. doi: 10.1158/2326-6066.CIR-17-0443. Epub 2018 Sep 18. Erratum in: Cancer Immunol Res. 2019 Jan;7(1):162.

PMID:
30228206
5.

A very rare interference with the valproate method on the Beckman DxC 800 general chemistry analyser.

Dimeski G, Treacy O, Marshall G.

Clin Chem Lab Med. 2019 Mar 26;57(4):e67-e70. doi: 10.1515/cclm-2018-0716. No abstract available.

PMID:
30157029
6.

Interspecies Incompatibilities Limit the Immunomodulatory Effect of Human Mesenchymal Stromal Cells in the Rat.

Lohan P, Treacy O, Morcos M, Donohoe E, O'donoghue Y, Ryan AE, Elliman SJ, Ritter T, Griffin MD.

Stem Cells. 2018 Aug;36(8):1210-1215. doi: 10.1002/stem.2840. Epub 2018 May 16.

7.

Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?

Lohan P, Treacy O, Griffin MD, Ritter T, Ryan AE.

Front Immunol. 2017 Nov 24;8:1626. doi: 10.3389/fimmu.2017.01626. eCollection 2017. Review.

8.

Regulating Immunogenicity and Tolerogenicity of Bone Marrow-Derived Dendritic Cells through Modulation of Cell Surface Glycosylation by Dexamethasone Treatment.

Lynch K, Treacy O, Gerlach JQ, Annuk H, Lohan P, Cabral J, Joshi L, Ryan AE, Ritter T.

Front Immunol. 2017 Oct 30;8:1427. doi: 10.3389/fimmu.2017.01427. eCollection 2017.

9.

Mesenchymal stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translation.

Murphy N, Lynch K, Lohan P, Treacy O, Ritter T.

Curr Opin Organ Transplant. 2016 Dec;21(6):559-567. Review.

PMID:
27801687
10.

Corneal Immunosuppressive Mechanisms, Anterior Chamber-Associated Immune Deviation (ACAID) and Their Role in Allograft Rejection.

Treacy O, Fahy G, Ritter T, O'Flynn L.

Methods Mol Biol. 2016;1371:205-14. doi: 10.1007/978-1-4939-3139-2_13. Review.

PMID:
26530803
11.

Culture expanded primary chondrocytes have potent immunomodulatory properties and do not induce an allogeneic immune response.

Lohan P, Treacy O, Lynch K, Barry F, Murphy M, Griffin MD, Ritter T, Ryan AE.

Osteoarthritis Cartilage. 2016 Mar;24(3):521-33. doi: 10.1016/j.joca.2015.10.005. Epub 2015 Oct 19.

12.

Mesenchymal stem cell therapy promotes corneal allograft survival in rats by local and systemic immunomodulation.

Treacy O, O'Flynn L, Ryan AE, Morcos M, Lohan P, Schu S, Wilk M, Fahy G, Griffin MD, Nosov M, Ritter T.

Am J Transplant. 2014 Sep;14(9):2023-36. doi: 10.1111/ajt.12828. Epub 2014 Aug 6.

13.

Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation.

Ryan AE, Lohan P, O'Flynn L, Treacy O, Chen X, Coleman C, Shaw G, Murphy M, Barry F, Griffin MD, Ritter T.

Mol Ther. 2014 Mar;22(3):655-667. doi: 10.1038/mt.2013.261. Epub 2013 Nov 1.

14.

Donor bone marrow-derived dendritic cells prolong corneal allograft survival and promote an intragraft immunoregulatory milieu.

O'Flynn L, Treacy O, Ryan AE, Morcos M, Cregg M, Gerlach J, Joshi L, Nosov M, Ritter T.

Mol Ther. 2013 Nov;21(11):2102-12. doi: 10.1038/mt.2013.167. Epub 2013 Jul 18.

15.

Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?

Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T.

Immunol Cell Biol. 2013 Jan;91(1):40-51. doi: 10.1038/icb.2012.67. Epub 2012 Dec 4. Review.

PMID:
23207278
16.

Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation.

Treacy O, Ryan AE, Heinzl T, O'Flynn L, Cregg M, Wilk M, Odoardi F, Lohan P, O'Brien T, Nosov M, Ritter T.

PLoS One. 2012;7(8):e42662. doi: 10.1371/journal.pone.0042662. Epub 2012 Aug 6.

17.

Role of lentivirus-mediated overexpression of programmed death-ligand 1 on corneal allograft survival.

Nosov M, Wilk M, Morcos M, Cregg M, O'Flynn L, Treacy O, Ritter T.

Am J Transplant. 2012 May;12(5):1313-22. doi: 10.1111/j.1600-6143.2011.03948.x. Epub 2012 Feb 2.

18.

Immunogenicity of allogeneic mesenchymal stem cells.

Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, Murphy M, O'Brien T, Ritter T.

J Cell Mol Med. 2012 Sep;16(9):2094-103. doi: 10.1111/j.1582-4934.2011.01509.x.

19.

An anaesthetic pre-operative assessment clinic reduces pre-operative inpatient stay in patients requiring major vascular surgery.

O'Connor DB, Cotter M, Treacy O, Owens T, McShane A, Mehigan D, Sheehan SJ, Barry MC.

Ir J Med Sci. 2011 Sep;180(3):649-53. doi: 10.1007/s11845-011-0703-7. Epub 2011 Mar 24.

PMID:
21431923
20.

Supplemental Content

Loading ...
Support Center